Justin David Finkle

Title: Innovations by Justin David Finkle

Introduction

Justin David Finkle is an accomplished inventor based in Chicago, IL. He has made significant contributions to the field of liquid biopsy assays, holding 2 patents that showcase his innovative approach to cancer diagnostics. His work focuses on improving the accuracy and reliability of somatic sequence variant validation.

Latest Patents

Finkle's latest patents include "Methods and systems for dynamic variant thresholding in a liquid biopsy assay." This invention provides methods, systems, and software for validating somatic sequence variants in subjects with cancer. The process involves obtaining sequence reads from cell-free DNA fragments in a liquid biopsy sample, aligning them to a reference sequence, and comparing variant allele fragment counts against a dynamic threshold based on pre-test odds. This innovation enhances the validation process for somatic sequence variants.

Another notable patent is "Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing." This invention offers methods, systems, and software for estimating circulating tumor fractions in test subjects. It involves analyzing sequence reads from a panel-enriched sequencing reaction and determining segment-level coverage ratios. The circulating tumor fraction is then estimated using error optimization, providing a more accurate assessment of tumor presence in the subject.

Career Highlights

Justin David Finkle is currently employed at Tempus Labs, Inc., where he continues to develop cutting-edge technologies in the field of genomics and cancer diagnostics. His work at Tempus Labs has positioned him as a key player in advancing personalized medicine through innovative solutions.

Collaborations

Finkle collaborates with talented professionals in his field, including coworkers Terri M Driessen and Christine Lo. Their combined expertise contributes to the success of projects aimed at improving cancer detection and treatment.

Conclusion

Justin David Finkle's contributions to the field of liquid biopsy assays demonstrate his commitment to innovation in cancer diagnostics. His patents reflect a deep understanding of the complexities involved in somatic variant validation and tumor fraction estimation. Through his work at Tempus Labs, he continues to push the boundaries of what is possible in personalized medicine.